China Pharma Holdings Shares Outstanding 2012-2026 | CPHI
China Pharma Holdings shares outstanding from 2012 to 2026. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
|
China Pharma Holdings Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2025 | 4 |
| 2024 | 2 |
| 2023 | 0 |
| 2022 | 0 |
| 2021 | 0 |
| 2020 | 0 |
| 2019 | 0 |
| 2018 | 0 |
| 2017 | 0 |
| 2016 | 0 |
| 2015 | 0 |
| 2014 | 0 |
| 2013 | 0 |
| 2012 | 0 |
| 2011 | 0 |
|
China Pharma Holdings Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2026-03-31 | 26 |
| 2025-12-31 | 4 |
| 2025-09-30 | 4 |
| 2025-06-30 | 3 |
| 2025-03-31 | 3 |
| 2024-12-31 | 2 |
| 2024-09-30 | 2 |
| 2024-06-30 | 2 |
| 2024-03-31 | 1 |
| 2023-12-31 | 0 |
| 2023-09-30 | 0 |
| 2023-06-30 | 0 |
| 2023-03-31 | 0 |
| 2022-12-31 | 0 |
| 2022-09-30 | 0 |
| 2022-06-30 | 0 |
| 2022-03-31 | 0 |
| 2021-12-31 | 0 |
| 2021-09-30 | 0 |
| 2021-06-30 | 0 |
| 2021-03-31 | 0 |
| 2020-12-31 | 0 |
| 2020-09-30 | 0 |
| 2020-06-30 | 0 |
| 2020-03-31 | 0 |
| 2019-12-31 | 0 |
| 2019-09-30 | 0 |
| 2019-06-30 | 0 |
| 2019-03-31 | 0 |
| 2018-12-31 | 0 |
| 2018-09-30 | 0 |
| 2018-06-30 | 0 |
| 2018-03-31 | 0 |
| 2017-12-31 | 0 |
| 2017-09-30 | 0 |
| 2017-06-30 | 0 |
| 2017-03-31 | 0 |
| 2016-12-31 | 0 |
| 2016-09-30 | 0 |
| 2016-06-30 | 0 |
| 2016-03-31 | 0 |
| 2015-12-31 | 0 |
| 2015-09-30 | 0 |
| 2015-06-30 | 0 |
| 2015-03-31 | 0 |
| 2014-12-31 | 0 |
| 2014-09-30 | 0 |
| 2014-06-30 | 0 |
| 2014-03-31 | 0 |
| 2013-12-31 | 0 |
| 2013-09-30 | 0 |
| 2013-06-30 | 0 |
| 2013-03-31 | 0 |
| 2012-12-31 | 0 |
| 2012-09-30 | 0 |
| 2012-06-30 | 0 |
| 2012-03-31 | 0 |
| 2011-12-31 | 0 |
| 2011-09-30 | 0 |
| 2011-06-30 | 0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.026B | $0.004B |
| CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |